Literature DB >> 2982504

The early (18-hr) human mixed lymphocyte reaction: identification and isolation of activated T-cell clones.

A A Ythier, J M Williams, H M Shapiro, V E Kelley, T B Strom.   

Abstract

This study provides direct evidence that de novo expression of the activation antigens B1 49.9 (49.9) (interleukin-2 receptor) and 4F2 enables identification of alloactivated cells within 18 hr of initiation of human mixed lymphocyte reactions (MLR). Using a dual-parameter flow cytometer (simultaneous assessment of immunofluorescence and DNA content on the same cell), it was demonstrated that these activation antigens emerge before activated cells enter into S/G2/M phase of the cell cycle. Family studies illustrate that early activation antigen appearance occurs in response to a mismatch at chromosome 6, and invariably heralds the proliferative outcome at 6 days of MLR. In order to directly study the small alloactivated T-cell population, 49.9-positive cells were isolated using a cell sorter after 18 hr of MLR and cloned by limiting dilution using purified recombinant interleukin-2 (rIL-2). Antigen-specific T4-positive T-cell clones were isolated. Analysis of these clones demonstrates that antigen-specific reactivity is acquired within 18 hr in the MLR. These methods should permit a dissection of the early events of alloactivation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982504     DOI: 10.1016/0008-8749(85)90045-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  2006 Homer W. Smith Lecture: taming T cells.

Authors:  Terry B Strom
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

2.  Interleukin 2-dependent release of interleukin 3 activity by T4+ human T-cell clones.

Authors:  A A Ythier; M Abbud-Filho; J M Williams; R Loertscher; M W Schuster; A Nowill; J A Hansen; D Maltezos; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.